When people have Alzheimer’s disease, their brains slowly accumulate abnormal clumps of two proteins: amyloid and tau. At ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

Blood tests and the adoption of AI in cognitive decline screenings have opened the door to new avenues for testing cognitive ...

At the Human Amyloid Imaging (HAI) meeting, held January 15-17, researchers focused on new techniques—all based on tau and ...

In related news, other scientists recently reported that phospho-tau isoforms in the CSF mirror protofibrillar forms of tau, ...

Researchers have developed a test that spots early signs of Alzheimer's disease. Rather than looking for amyloid-beta plaques ...

A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...

Currently, although brain Abeta accumulation can be detected by positron emission tomography(4) (amyloid PET) and cerebrospinal fluid testing(5) (CSF testing), the high cost and invasiveness of ...

Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...